REG - MyHealthChecked PLC - Launch of at-home wellness tests

MyhealthcheckedAnnouncement

14/06/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220614:nRSN7152Oa&default-theme=true

RNS Number : 7152O  MyHealthChecked PLC  14 June 2022

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

 

MyHealthChecked plc

("MyHealthChecked" or "the Company")

 

Launch of at-home wellness tests

MyHealthChecked launches five new DNA tests into the consumer home-testing
market

 

MyHealthChecked Plc (AIM: MHC), the consumer home-testing healthcare company,
announces that it has launched five new at-home cheek swab DNA wellness tests,
enabling individuals to make more informed choices about their health and
well-being by providing a better understanding of their genetic disposition.
The tests are designed to give individuals the power to be more proactive in
unlocking their health potential through the management of diet and lifestyle.

 

Each of the tests will be priced at £54 and the tests currently available to
purchase are:

·    Intolerances & Sensitivities - to identify genetic variants
associated with intolerances, such as gluten and lactose, as well as
sensitivities, including caffeine, salt and alcohol

·  Weight Management - intended for use by those wishing to identify their
genetic susceptibility to becoming overweight and their responsiveness to
weight loss interventions at a molecular and metabolic level, including
genetic interactions

·    Heart Profile - identifying how individuals respond differently to
diet. This will facilitate optimisation of heart health parameters by using
personalised dietary advice

·    Vitamins & Minerals - this test indicates the predisposition
towards a nutrient deficiency or toxicity, to highlight nutrients or
supplements an individual should increase or deprioritise

·    Glucose Management - for individuals who aim to follow a tailored
diet to adjust their intake of specific nutrients or foods to improve their
glucose response

 

The tests will require individuals to take a simple cheek swab and return
their swab in the pre-paid envelope back to MyHealthChecked's UK lab where
data will be handled securely and accurately. Customers will then be able to
access personalised reports, advice and guidance based on their results
through the MyHealthChecked portal.

 

All five wellness tests will be available to purchase on the Company's website
later today:

https://myhealthchecked.com/ (https://myhealthchecked.com/)

 

Penny McCormick, Chief Executive Officer of MyHealthChecked Plc, said: "I am
delighted to announce the launch of our new suite of at-home wellness tests
and I am proud of the efforts of the MyHealthChecked team that have allowed us
to reach this milestone on time. This is a significant achievement as we move
into a new phase of the business outside of the COVID-19 testing space.

 

"These initial tests are just the start of our consumer testing portfolio, and
we look forward to updating the market on further portfolio developments
throughout the course of 2022. Going forward we will continue to engage with
the market on potential opportunities and re-invest the 2021 earnings from our
COVID testing services to explore additional third-party technology options to
further enhance the customer journey for our wellness tests. We also continue
our efforts to identify and assess complementary earnings-enhancing
partnerships."

 

For further information contact:

 

 MyHealthChecked plc                                                www.myhealthchecked.com (http://www.myhealthchecked.com)
 Penny McCormick, Chief Executive Officer                           via Walbrook PR

 SPARK Advisory Partners Limited (NOMAD)                            Tel: +44 (0)20 3368 3550
 Neil Baldwin

 Oberon Capital Ltd (Broker)                                        Tel: +44 (0)203 179 5344
 Mike Seabrook                                                      mikeseabrook@oberoninvestments.com (mailto:mikeseabrook@oberoninvestments.com)

 Walbrook PR Ltd (Media & IR)      Tel: +44 (0)20 7933 8780 or myhealthcheckedplc@walbrookpr.com
                                   (mailto:myhealthcheckedplc@walbrookpr.com)
 Paul McManus / Alice Woodings                                      Mob: +44(0)7980 541 893 / +44(0) 7407 804 654

 

About MyHealthChecked PLC (www.myhealthcheckedplc.com
(http://www.myhealthcheckedplc.com) )

MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK
healthcare company focused on a range of at-home healthcare and wellness
tests.

 

MyHealthChecked is the umbrella brand of a range of at-home DNA and RNA tests,
now in development following the acquisition of The Genome Store in November
2020. The tests will be made available online, and would be viable for over
the counter purchase.

 

The MyHealthChecked portfolio has been identified as part of a change in
mindset as customers become more familiar with the concept of accessible
healthcare in the growing at home testing kit market with a focus on
accessibility at the right price, led by UK-based experts.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDUOSNRUWUNAAR